Literature DB >> 10085130

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

R Worthylake1, L K Opresko, H S Wiley.   

Abstract

ErbB-2/HER2 is an important signaling partner for the epidermal growth factor receptor (EGFR). Overexpression of erbB-2 is also associated with poor prognosis in breast cancer. To investigate how erbB-2 amplification affects its interactions with the EGFR, we used a human mammary epithelial cell system in which erbB-2 expression was increased 7-20-fold by gene transfection. We found that amplification of erbB-2 caused constitutive activation of erbB-2 as well as ligand-independent activation of the EGFR. Overexpression of erbB-2 strongly inhibited erbB-2 down-regulation following transactivation by EGFR. Significantly, down-regulation of activated EGFR was also inhibited by erbB-2 amplification, resulting in enhanced ligand-dependent activation of the EGFR. The rate of EGFR endocytosis was not affected by erbB-2 overexpression, but the rate of lysosomal targeting was significantly reduced. In addition, erbB-2 overexpression promoted rapid recycling of activated EGFR back to the cell surface and decreased ligand dissociation from the EGFR. Our data suggest that overexpression of erbB-2 inhibits both its down-regulation and that of the EGFR. The net effect is increased signaling through the EGFR system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085130     DOI: 10.1074/jbc.274.13.8865

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  98 in total

1.  Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor.

Authors:  D C Márquez; J Lee; T Lin; R J Pietras
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

2.  Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis.

Authors:  Peter Nagy; Jeroen Claus; Thomas M Jovin; Donna J Arndt-Jovin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-02       Impact factor: 11.205

3.  Coclustering of ErbB1 and ErbB2 revealed by FRET-sensitized acceptor bleaching.

Authors:  Agnes Szabó; János Szöllosi; Peter Nagy
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

Review 4.  [Principles and method of action of targeted therapies].

Authors:  Christian F Singer
Journal:  Wien Med Wochenschr       Date:  2010-08-24

5.  Stepwise movements in vesicle transport of HER2 by motor proteins in living cells.

Authors:  Tomonobu M Watanabe; Hideo Higuchi
Journal:  Biophys J       Date:  2007-03-16       Impact factor: 4.033

6.  Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.

Authors:  Mads Lerdrup; Silas Bruun; Michael V Grandal; Kirstine Roepstorff; Malene M Kristensen; Anette M Hommelgaard; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

Review 7.  Effects of membrane trafficking on signaling by receptor tyrosine kinases.

Authors:  Marta Miaczynska
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

8.  Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.

Authors:  Agnes Szabó; Gábor Horváth; János Szöllosi; Peter Nagy
Journal:  Biophys J       Date:  2008-05-16       Impact factor: 4.033

Review 9.  Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

Authors:  Byung Min Chung; Eric Tom; Neha Zutshi; Timothy Alan Bielecki; Vimla Band; Hamid Band
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.

Authors:  Carlos L Arteaga; Anne O'Neill; Stacy L Moulder; Michael Pins; Joseph A Sparano; George W Sledge; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.